Compare SNDA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDA | ADMA |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1997 | 2012 |
| Metric | SNDA | ADMA |
|---|---|---|
| Price | $37.77 | $9.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $49.50 | $17.00 |
| AVG Volume (30 Days) | 342.0K | ★ 2.4M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.35 |
| Revenue | ★ $381,141,000.00 | $42,219,783.00 |
| Revenue This Year | $120.42 | $4.93 |
| Revenue Next Year | $17.55 | $17.59 |
| P/E Ratio | ★ N/A | $28.46 |
| Revenue Growth | 25.24 | ★ 43.85 |
| 52 Week Low | $24.95 | $7.21 |
| 52 Week High | $44.39 | $20.46 |
| Indicator | SNDA | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 61.24 |
| Support Level | $36.90 | $9.23 |
| Resistance Level | $39.18 | $10.24 |
| Average True Range (ATR) | 1.05 | 0.39 |
| MACD | -0.07 | 0.09 |
| Stochastic Oscillator | 24.09 | 95.08 |
Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic services offered by the company at its senior housing communities comprise meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.